Bronwyn J. Levvey

Bronwyn J. Levvey

Auto-generated profile, based on publicly available information

Bronwyn J. Levvey

Lung Transplant Service, Alfred Hospital and Monash University, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
KKKiran K. Khush
Kiran K. Khush
WCWida S. Cherikh
Wida S. Cherikh
DCDaniel C. Chambers
Daniel C. Chambers
SGSamuel Goldfarb
Samuel Goldfarb
DHDon Hayes
Don Hayes
JSJosef Stehlik
Josef Stehlik

1 October 2018 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DCDaniel C. Chambers
Daniel C. Chambers
WCWida S. Cherikh
Wida S. Cherikh
SGSamuel B. Goldfarb
Samuel B. Goldfarb
DHDon Hayes
Don Hayes
AKAnna Y. Kucheryavaya
Anna Y. Kucheryavaya
JSJosef Stehlik
Josef Stehlik

1 September 2012 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
BLB. J. Levvey
B. J. Levvey
MHM. Harkess
M. Harkess
PHP. Hopkins
P. Hopkins
DCD. Chambers
D. Chambers
CMC. Merry
C. Merry
GSG. I. Snell
G. I. Snell
Donation-after-Determination-of-Cardiac-Death (DDCD) donor lungs can potentially increase the pool of lungs available for Lung Transplantation (LTx). This paper presents the 5-year results for Maastricht category III DDCD LTx undertaken by the multicenter Australian National DDCD LTx Collaborative. The Collaborative was developed to facilitate interaction with the Australian Organ Donation Authority, standardization of definitions, guidelines, education and audit processes. Between 2006 and 2011 there were 174 actual DDCD category III donors (with an additional 37 potentially suitable donors who did not arrest in the mandated 90 min postwithdrawal window), of whom 71 donated lungs for 70 bilateral LTx and two single LTx. In 2010 this equated to an "extra" 28% of donors utilized for LTx. Withdrawal to pulmonary arterial flush was a mean of 35.2 ± 4.0 min (range 18-89). At 24 h, the incidence of grade 3 primary graft dysfunction was 8.5%[median PaO(2)/FiO(2) ratio 315 (range 50-507)]. Overall the incidence of grade 3 chronic rejections was 5%. One- and 5-year actuarial survival was 97% and 90%, versus 90% and 61%, respectively, for 503 contemporaneous brain-dead donor lung transplants. Category III DDCD LTx therefore provides a significant, practical, additional quality source of transplantable lungs.

27 July 2011 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MPM. Paraskeva
M. Paraskeva
MBMichael Bailey
Michael Bailey
BLB. J. Levvey
B. J. Levvey
AGA. P. Griffiths
A. P. Griffiths
TKT. C. Kotsimbos
T. C. Kotsimbos
GWG. Westall
G. Westall
Early studies reported cytomegalovirus (CMV) pneumonitis as a risk factor for development of bronchiolitis obliterans syndrome (BOS) following lung transplantation. While improvements in antiviral prophylaxis have resulted in a decreased incidence of CMV pneumonitis, molecular diagnostic techniques allow diagnosis of subclinical CMV replication in the allograft. We hypothesized that this subclinical CMV replication was associated with development of BOS. We retrospectively evaluated 192 lung transplant recipients (LTR) from a single center between 2001 and 2009. Quantitative (PCR) analysis of CMV viral load and histological evidence of CMV pneumonitis and acute cellular rejection was determined on 1749 bronchoalveolar lavage (BAL) specimens and 1536 transbronchial biopsies. CMV was detected in the BAL of 41% of LTR and was significantly associated with the development of BOS (HR 1.8 [1.1–2.8], p = 0.02). This association persisted when CMV was considered more accurately as a time-dependent variable (HR 2.1 [1.3–3.3], p = 0.003) and after adjustment for significant covariates in a multivariate model. CMV replication in the lung allograft is common following lung transplantation and is associated with increased risk of BOS. As antiviral prophylaxis adequately suppresses CMV longer prophylactic strategies may improve long-term outcome in lung transplantation.

1 January 2007 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
TOTakahiro Oto
Takahiro Oto
BLBronwyn J. Levvey
Bronwyn J. Levvey
HWHelen Whitford
Helen Whitford
AGAnne P. Griffiths
Anne P. Griffiths
TKTom Kotsimbos
Tom Kotsimbos
GSGregory I. Snell
Gregory I. Snell

1 February 2011 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
CNC. F. Neoh
C. F. Neoh
GSG. I. Snell
G. I. Snell
TKT. Kotsimbos
T. Kotsimbos
BLB. Levvey
B. Levvey
CMC. O. Morrissey
C. O. Morrissey
DKD. C. M. Kong
D. C. M. Kong
While variations in antifungal prophylaxis have been previously reported in lung transplant (LTx) recipients, recent clinical practice is unknown. Our aim was to determine current antifungal prophylactic practice in LTx centers world-wide. One nominated LTx clinician from each active center was invited by e-mail to participate in a web-based survey between September 2009 and January 2010. Fifty-seven percent (58/102) responded. The majority of responses were from medical directors of LTx centers (72.4%), and from the United States (44.8%). Within the first 6 months post-LTx, most centers (58.6%) employed universal prophylaxis, with 97.1% targeting Aspergillus species. Voriconazole alone, and in combination with inhaled amphotericin B (AmB), were the preferred first-line agents. Intolerance to side effects of voriconazole (69.2%) was the main reason for switching to alternatives. Beyond 6 months post-LTx, most (51.8%) did not employ antifungal prophylaxis. Fifteen centers (26.0%) conducted routine antifungal therapeutic drug monitoring during prophylactic period. There are differences in strategies employed between U.S. and European centers. Most respondents indicated a need for antifungal prophylactic guidelines. In comparison to earlier findings, there was a major shift toward prophylaxis with voriconazole and an increased use of echinocandins, posaconazole and inhaled lipid formulation AmB.